Raynaud's Syndrome (Primary)
Investigational use for primary Raynaud's phenomenon; mechanism via local vasodilation and rheologic improvement. No RCT evidence.
Patienten-Zusammenfassung
- Ist dies FDA-zugelassen fuer diese Anwendung?
- Not FDA-cleared for Raynaud's syndrome. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for primary Raynaud's is investigational.
- Welche Evidenz existiert?
- Tier C (investigational). Case reports and a small series describe improvement in attack frequency or severity after 2-3 sessions placed on the hands. There are no randomized controlled trials. Secondary Raynaud's (scleroderma, lupus, antiphospholipid syndrome) requires rheumatology workup. Evidence-based first-line care for primary Raynaud's is conservative measures (warmth, trigger avoidance, smoking cessation) and calcium-channel blockers (nifedipine, amlodipine).
- Hauptrisiken
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness on the dorsum of the hands for 5 to 10 days
- Itching and irritation at bite sites
- Local skin infection or, rarely, Aeromonas infection (especially concerning in patients with compromised distal circulation)
- Allergic reaction to leech saliva (uncommon)
- Potential digital ulceration or impaired healing if applied to ischemic fingers
- Small permanent scars at bite sites
- Wer dies nicht in Betracht ziehen sollte
- Patients on blood thinners (warfarin INR >2.0, DOACs, heparin)
- Patients with hemophilia or other bleeding disorders
- Patients with severe anemia (Hb <10 g/dL)
- Patients with secondary Raynaud's and active vasculitis or critical digital ischemia
- Patients with active digital ulceration
- Patients with scleroderma until evaluated and treated by rheumatology
- Patients with a weakened immune system
- Was Sie Ihren Kliniker fragen sollten
- Have I been evaluated for secondary causes (scleroderma, lupus, antiphospholipid syndrome)?
- Have I tried trigger avoidance, warmth strategies, smoking cessation, and calcium-channel blockers?
- What evidence supports leech therapy for Raynaud's specifically?
- How will distal circulation and skin integrity be assessed before placement?
- What is the practitioner's experience and Aeromonas-prevention plan?
- What is the realistic chance of benefit, and for how long?
- What is the cost, and what does it commit me to?
- Wann dringende medizinische Versorgung suchen
- Persistent digital pallor or cyanosis lasting hours, especially with pain
- New digital ulcers or skin breakdown that won't heal
- Bleeding from bite sites lasting more than 24 to 48 hours
- Spreading redness, warmth, pus, or red streaks (cellulitis)
- Fever above 38.0 C / 100.4 F or chills
- Hives, throat tightness, or breathing difficulty
Was dies NICHT bedeutet
- This is not FDA-cleared for Raynaud's syndrome.
- Case reports are not evidence of efficacy in the general population.
- Mechanism rationale (local vasodilation, rheologic improvement) does NOT establish clinical efficacy.
- Leech therapy does not address secondary Raynaud's underlying disease (scleroderma, lupus).
- Leech therapy is not a substitute for conservative measures and calcium-channel blockers.
Sicherheits-Querverweise
Clinical Profile
- Category
- vascular
- ICD-10
- I73.00, I73.01
- Safety tier
- medium
Evidence Summary
Evidence for leech therapy in Raynaud's phenomenon is limited to anecdotal reports; a recent Azerbaijan clinical case series (Farzali et al. 2025) included only 3 patients with Raynaud disease, far too few to establish efficacy. The proposed mechanism involves local vasodilation from salivary vasoactive peptides plus systemic rheologic improvement from absorbed hirudin, but no controlled trials exist. Secondary Raynaud's (associated with scleroderma, lupus, and similar conditions) should be evaluated separately, as treatment of the underlying disease is primary. ASH position: not first-line and investigational; first-line is conservative measures (warmth, avoiding triggers) followed by calcium-channel blockers.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Khurram K et al. (2017), n=8
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Critical limb ischemia
- Active digital ulceration or gangrene
- Secondary Raynaud's with active vasculitis
Related ASH Compounds
Leech-derived molecules implicated in this condition, each profiled in the ASH compound registry:
Related Conditions
Chronic Venous Insufficiency (CEAP C3-C5)
Off-label use with controlled trial evidence for symptomatic improvement in venous claudication, leg heaviness, and edema in CEAP C3-C5 stages.
Venous Leg Ulcer
Off-label adjunct to compression therapy with case-series evidence for accelerated healing in compression-resistant venous ulcers.
Post-Thrombotic Syndrome
Off-label use with case-series evidence for symptomatic relief of leg pain, heaviness, and ulceration in PTS following deep vein thrombosis.
Varicose Veins (Symptomatic Tributaries)
Investigational use for symptomatic relief of varicose tributary discomfort and inflammation; does not eliminate underlying venous reflux.